Roche’s drug, Actemra (tocilizumab) intravenous, is intended for a single, 1-hour infusion. The FDA approved it for the treatment of hospitalized COVID-19 adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation, according to a Roche news release.
Eli Lilly’s bebtelovimab had emergency use authorization for about nine months until Nov. 30, when the FDA revoked the EUA because omicron subvariants BQ.1 and BQ.1.1 “showed a large reduction in susceptibility,” or a 672-fold drop, to the monoclonal antibody.
Before becoming the first FDA-approved monoclonal antibody to treat COVID-19, Actemra received emergency use authorization in June 2021.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
